Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.51 |
| ▸ | MET | P08581 | 8/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472117 | 0.99 | ALK (0.51) | ALKMETHRH3CSF1RRXRA | |
| SCHEMBL3473698 | 0.91 | RXRA (0.49) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3473375 | 0.88 | RXRA (0.47) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3473893 | 0.88 | RXRA (0.49) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3472116 | 0.88 | RXRA (0.48) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3478025 | 0.88 | RXRA (0.48) | ALKMETHRH3CSF1RRXRA | |
| SCHEMBL3473931 | 0.86 | RXRA (0.45) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3473694 | 0.85 | RXRA (0.46) | ALKMETRXRANR1H2NR1H3 | |
| SCHEMBL3474693 | 0.85 | RXRA (0.46) | ALKRXRANR1H2NR1H3 | |
| SCHEMBL3472172 | 0.85 | RXRA (0.46) | ALKRXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | ALK 3231/4885MET 1245/4885HRH3 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.